Leveraging Non-Invasive Approaches in NAFLD and NASH Diagnosis and Clinical Research
Dr. Sabina Paglialunga of Celerion addresses the merits and limitations of non-invasive NAFLD/NASH diagnosis and treatment monitoring modalities such as ultrasound, magnetic resonance and elastography. Panels of soluble biomarkers that can distinguish between advanced fibrosis, NASH and fatty liver are also discussed.
ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA 2017
The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader.
ALPCO and InSphero Collaborate to Advance Metabolic Disease Research at ADA 2017
ALPCO and InSphero will team up at the ADA’s 77th Scientific Sessions to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring glucagon secretion and glucose-regulated insulin assays.
The Impact of Adiponectin in NAFLD and NASH Research
This blog post discusses the growing popularity of using adiponectin in NAFLD and NASH research, and highlights current research with the biomarker.
Choosing the Relevant GLP-1 Species to Study
This blog discusses how the GLP-1 lifecycle can play a role in choosing the relevant GLP-1 species to study.